775 related articles for article (PubMed ID: 17200266)
1. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
2. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
Clark HF; Burke CJ; Volkin DB; Offit P; Ward RL; Bresee JS; Dennehy P; Gooch WM; Malacaman E; Matson D; Walter E; Watson B; Krah DL; Dallas MJ; Schödel F; Kaplan kM; Heaton P
Pediatr Infect Dis J; 2003 Oct; 22(10):914-20. PubMed ID: 14551493
[TBL] [Abstract][Full Text] [Related]
6. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis.
Heaton PM; Goveia MG; Miller JM; Offit P; Clark HF
J Infect Dis; 2005 Sep; 192 Suppl 1():S17-21. PubMed ID: 16088800
[TBL] [Abstract][Full Text] [Related]
7. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
Dennehy PH; Goveia MG; Dallas MJ; Heaton PM
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S36-42. PubMed ID: 18162245
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.
Vesikari T; Karvonen AV; Majuri J; Zeng SQ; Pang XL; Kohberger R; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
J Infect Dis; 2006 Aug; 194(3):370-6. PubMed ID: 16826486
[TBL] [Abstract][Full Text] [Related]
10. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
Clark HF; Offit PA; Plotkin SA; Heaton PM
Pediatr Infect Dis J; 2006 Jul; 25(7):577-83. PubMed ID: 16804425
[TBL] [Abstract][Full Text] [Related]
11. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
Ciarlet M; Schödel F
Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
[TBL] [Abstract][Full Text] [Related]
12. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea.
Kim DS; Lee TJ; Kang JH; Kim JH; Lee JH; Ma SH; Kim SY; Kim HM; Shin SM
Pediatr Infect Dis J; 2008 Feb; 27(2):177-8. PubMed ID: 18174862
[TBL] [Abstract][Full Text] [Related]
14. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
Vesikari T; Matson DO; Dennehy P; Van Damme P; Santosham M; Rodriguez Z; Dallas MJ; Heyse JF; Goveia MG; Black SB; Shinefield HR; Christie CD; Ylitalo S; Itzler RF; Coia ML; Onorato MT; Adeyi BA; Marshall GS; Gothefors L; Campens D; Karvonen A; Watt JP; O'Brien KL; DiNubile MJ; Clark HF; Boslego JW; Offit PA; Heaton PM;
N Engl J Med; 2006 Jan; 354(1):23-33. PubMed ID: 16394299
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus live, oral, pentavalent vaccine.
Tom-Revzon C
Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
[TBL] [Abstract][Full Text] [Related]
17. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
[TBL] [Abstract][Full Text] [Related]
20. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
